Therini Bio Closes $39M Series A to Unlock First-in-Class Immunotherapies for Neuroinflammatory Disorders

Therini Bio, Inc. Bio is thrilled to announce that it has successfully raised $39 million in its latest funding round, marking a significant milestone in its journey as a clinical-stage biotech innovator. This substantial investment will accelerate Therini Bio’s pioneering efforts to develop first-in-class immunotherapies targeting neuroinflammation in diseases driven by vascular dysfunction, such as Alzheimer’s disease (AD) and Diabetic Macular Edema (DME). The company's groundbreaking pipeline focuses on selectively neutralizing toxic fibrin accumulation, a pathology that underpins destructive neuroinflammatory responses in these conditions. Building on foundational science licensed from the esteemed Katerina Akassoglou’s laboratories at UCSF and former research at UCSD, Therini Bio is uniquely positioned to transform neuroinflammatory treatment paradigms with precision-targeted therapies. The funds will be strategically allocated to advancing clinical programs, enriching research and development capabilities, and expanding collaborative efforts with key partners in the field. Among its impressive investors are respected organizations such as the Alzheimer’s Drug Discovery Foundation, SV Health Investors’ Biotech Fund, Dementia Discovery Fund, Dolby Family Ventures, Eli Lilly and Company, and major industry players like Merck & Co., Inc. and Sanofi Ventures. This diverse syndicate underscores the trust and optimism the investment community has in Therini Bio’s innovative therapeutic approach and its potential to drive transformative advancements in neuroinflammation treatment. With this new funding, Therini Bio is poised to deepen its scientific endeavors, propel clinical trials, and ultimately, revolutionize care for patients suffering from debilitating neuroinflammatory diseases.